Our data extend these prior observations by demonstrating that KDM6A mutations, independent of expression changes, confer a high-risk phenotype characterized by shortened survival, even after adjusting for established prognostic factors such as age, cytogenetics, MRD, and ELN guidelines for AML risk stratification. The gene discussed is KDM6A; the disease is acute myeloid leukemia.